Coinfección COVID-19 y tuberculosis: experiencia de una terapia intensiva durante el periodo enero 2020-junio 2022 / COVID-19 and tuberculosis co-infection: experience of an intensive care unit during the period of January-june 2022

Antecedentes: Se ha demostrado que la coinfección tu-berculosis y COVID-19 presenta peor evolución clínica. La inmunidad protectora se debilita frente a esta situación, generando fallo en el control de ambas infecciones, reac-tivación de formas latentes de tuberculosis y progresión exacerbada de los casos activos. Asimismo, la terapia con corticoides utilizada dentro del tratamiento de infecciones graves por COVID-19 puede generar inmunosupresión y precipitar la progresión de la tuberculosis.Objetivos: Describir las características clínicas, presenta-ción y evolución de los pacientes críticos con coinfección COVID-19 y tuberculosis. Evaluar la incidencia y letalidad de la asociación COVID-19 y tuberculosis en cuidados in-tensivos. Materiales y métodos: Se realizó un estudio retrospectivo, descriptivo. Se revisaron 12 historias clínicas de pacientes con coinfección COVID-19-tuberculosis sobre 1014 histo-rias clínicas de pacientes ingresados con diagnóstico de COVID-19, durante el periodo comprendido enero 2020 y junio 2022. Se utilizó estadística descriptiva. Resultados y discusión: Sobre un total de 1014 historias clínicas, se encontraron 12 pacientes con coinfección (in-cidencia de 0,011). La letalidad global en cuidados inten-sivos fue del 75%, a los 45 días fue del 83,3%, duplicando la letalidad general de los pacientes COVID-19 no coinfec-tados ingresados durante el mismo periodo (75% versus 37%). Los pacientes que requirieron ingreso a ventilación RESUMENARTÍCULO ORIGINALmecánica tuvieron una letalidad del 100% y aquellos que tenían infección por virus de inmunodeficiencia adquirida presentaron una letalidad de 100%. Resulta importante describir los hallazgos y alertar sobre la evolución desfavorable de aquellos pacientes que pre-sentan esta asociación a fin de optimizar el manejo y espe-cialmente recomendar la búsqueda de coinfección cuando el criterio clínico lo requiera

Background: Coinfection with tuberculosis and COVID-19 has been shown to have a worse clinical course. Protective immunity is weakened in this situation, leading to failure to control both infections, reactivation of latent forms of TB and exacerbated progression of active cases. Furthermore, corticosteroid therapy used in the treatment of severe COVID-19 infections can lead to immunosuppression and precipitate TB progression.Objectives: To describe the clinical characteristics, presentation and evolution of critically ill patients with COVID-19 and tuberculosis co-infection.To evaluate the incidence and lethality of COVID-19 and tuberculosis association in intensive care.Materials and methods: A retrospective, descriptive study was conducted. Twelve medical records of patients aged 18 years or older admitted to intensive care with a diagnosis of COVID-19 during the period January 2020 to July 2022 were reviewed. Descriptive statistics were used.Results and discussion: Out of a total of 1014 medical records, 12 patients were found with co-infection (incidence 0.011). The global intensive care case fatality was 75%, at 45 days it was 83.3%. This was twice the overall case fatality of non-co-infected COVID-19 patients admitted during the same period (75% versus 37%). Patients requiring admission to mechanical ventilation had a 100% case fatality and those with acquired immunodeficiency virus infection had a 100% case fatality.It is important to describe the findings and to alert to the worse evolution of those patients presenting with this association, in order to improve management and recommend searching for co-infection when clinical criteria require it

COVID-19 impact on newly initiated and restarted antiretroviral treatment patients in the Eastern Cape, South Africa

Background: Initiating newly diagnosed people living with human immunodeficiency virus (HIV) onto antiretroviral treatment (ART) and retaining patients on treatment are vital to South Africa's ART programme. In 2020, coronavirus disease 2019 (COVID-19) and its accompanying containment (lockdown) measures presented unprecedented challenges to achieving these objectives. Aim: This study describes the impact of COVID-19 and related restrictions on district-level numbers of newly diagnosed people living with HIV and defaulting ART patients. Setting: Buffalo City Metropolitan Municipality (BCMM) in the Eastern Cape of South Africa. Methods: Mixed-methods approach: Monthly aggregated electronic patient data (newly initiated and restarted on ART) from 113 public healthcare (PHC) facilities were analysed (December 2019 to November 2020) across varying levels of COVID-19 lockdown regulation periods; telephonic in-depth interviews at 10 rural BCMM PHC facilities were conducted with facility staff, community health workers (CHWs) and intervention personnel. Results: The number of newly initiated ART patients decreased dramatically compared with pre-COVID-19 levels. The overall number of restarted ART patients increased in response to fears of co-infection with COVID-19. Facility-level communications and community outreach promoting HIV testing and treatment were disrupted. Novel approaches to providing services to ART patients were developed. Conclusion: Programmes for identifying undiagnosed people living with HIV and services aimed at retaining ART patients in care were profoundly impacted by COVID-19. The value of CHWs was highlighted, as were communication innovations. Contribution: This study describes the impact of COVID-19 and related regulations on HIV testing, ART initiation and adherence to treatment in a District of the Eastern Cape of South Africa.

Prevalence and seroprevalence of COVID-19 in suspected malaria during the second wave in Yaounde, Cameroon

Background. The COVID-19 pandemic has added an additional burden in countries with already fragile health systems. Our objective was to determine the prevalence and seroprevalence of COVID-19 in suspected malaria during the second wave in Yaounde. Methods. A descriptive cross-sectional study was conducted at the Jordan Medical Services for 8 weeks from April 19 to June 13, 2021, i.e., during the second wave in Cameroon. For the 86 patients with suspected malaria, nasopharyngeal and blood samples were taken for SARS-CoV-2 antigen and anti-SARS-CoV-2 IgG and IgM using the STANDARD TM Q COVID-19 Ag kit from SD BIOSENSOR, Korea, 2020 and Standard TM Q COVID 19 Ac IgG/IgM kit from SD BIOSENSOR, Korea, 2020 respectively. Confirmation of malaria was done by microscopic examination of stained blood smears. Results. Malaria was confirmed in 20.9% (18) of cases. The prevalences of COVID-19 and COVID-19/malaria co-infection were 8.1% and 0.9% respectively. Of the 25.6% (54) of patients with anti-COVID-19 IgM, no positive microscopic cases were found. On the other hand, a little more than half of the patients had IgG antibodies against COVID-19 whether they had a positive thick drop or not (56.0% (42/75) and 52.2% (71/136) respectively). Conclusion. In case of suspicion of malaria in a malaria area, it seems important to consider COVID-19 as a differential diagnosis.

Introduction. La pandémie de la COVID-19 a ajouté un fardeau supplémentaire dans les pays aux systèmes de santé déjà fragiles. Objectif : déterminer la prévalence et la séroprévalence de la COVID-19 en cas de suspicion du paludisme au cours de la deuxième vagueà Yaoundé. Méthodologie. Une étude transversale descriptive a été menée au Centre Médical le Jourdain pendant 8 semaines du 19 Avril au 13 Juin 2021 soit durant la deuxième vague au Cameroun. Pour les 86 patients avec suspicion de paludisme, des prélèvements nasopharyngé et sanguins ont été réalisés pour la recherche d'antigène du SRAS- CoV 2 et des IgG et IgM anti-SARS-CoV-2 grâce aux kits STANDARDTM Q COVID-19 Ag de SD BIOSENSOR, Corée, 2020 et StandardTM Q COVID 19 Ac IgG/IgM de SD BIOSENSOR, Corée, 2020 respectivement. La confirmation du paludisme a été faite grâce à l'examen microscopique des étalements de sang colorés. Résultats. Le paludisme était confirmé dans 20,9% (18) des cas. Les prévalences de la COVID-19 et de la coïnfection COVID19/Paludisme étaient de 8,1% et de 0,9% respectivement. Sur les 25,6% (54) des patients avec des IgM anti-COVID-19, aucun cas de microscopie positive n'a été retrouvé. Par ailleurs un peu plus de la moitié des patients avaient des anticorps IgG anti-COVID-19 qu'ils aient une goutte épaisse positive ou pas soit 56,0% (42/75) et 52,2% (71/136) respectivement. Conclusion. En cas de suspicion du paludisme en zone impaludée, il parait non négligeable de considérer la COVID-19 comme un diagnostic différentiel.

Factors associated with COVID-19 vaccine hesitancy among health personnel in Yaounde, Cameroon

Background. Health care personnel constitute a group at high risk of contracting COVID-19. However, the vaccination rate in this group in our context remains low. The objective of our study was to determine the factors associated with COVID-19 vaccine hesitancy among health care workers in Yaounde. Methods.We conducted a cross-sectional study of 360 health personnel in three hospitals in the city of Yaounde from January to March 2022, i.e., 3 months. All health personnel who gave their free consent were included. Ethical clearance was obtained from the Institutional Ethics and Research Committee of the Faculty of Medicine and Biomedical Sciences of the University of Yaounde I. A logistic regression was performed to search for factors associated with reluctance to vaccinate, with a significance level of 0.05. Results.The vaccination rate against COVID-19 was 34% (123). Factors associated with vaccine hesitancy were female gender (OR [95% CI] =3.5[2.2-5.5]; p<0.001), working outside a COVID-19 management unit (OR [95% CI]=6, [2.1-18.5]; p=0.001), fear of the harmfulness of COVID-19 vaccines (OR [CI 95%] =2.7[1.7-4.2]; p<0.001), and doubt of vaccine efficacy (OR [CI 95%] =4.0[2.5-6.4]; p<0.001). Conclusion:Health personnel are still reluctant to vaccinate in our context. Factors associated with hesitancy to vaccination against COVID-19 could help deconstruct apprehensions.

Introduction. La pandémie de la COVID-19 a ajouté un fardeau supplémentaire dans les pays aux systèmes de santé déjà fragiles. Objectif : déterminer la prévalence et la séroprévalence de la COVID-19 en cas de suspicion du paludisme au cours de la deuxième vagueà Yaoundé. Méthodologie. Une étude transversale descriptive a été menée au Centre Médical le Jourdain pendant 8 semaines du 19 Avril au 13 Juin 2021 soit durant la deuxième vague au Cameroun. Pour les 86 patients avec suspicion de paludisme, des prélèvements nasopharyngé et sanguins ont été réalisés pour la recherche d'antigène du SRAS- CoV 2 et des IgG et IgM anti-SARS-CoV-2 grâce aux kits STANDARDTM Q COVID-19 Ag de SD BIOSENSOR, Corée, 2020 et StandardTM Q COVID 19 Ac IgG/IgM de SD BIOSENSOR, Corée, 2020 respectivement. La confirmation du paludisme a été faite grâce à l'examen microscopique des étalements de sang colorés. Résultats. Le paludisme était confirmé dans 20,9% (18) des cas. Les prévalences de la COVID-19 et de la coïnfection COVID19/Paludisme étaient de 8,1% et de 0,9% respectivement. Sur les 25,6% (54) des patients avec des IgM anti-COVID-19, aucun cas de microscopie positive n'a été retrouvé. Par ailleurs un peu plus de la moitié des patients avaient des anticorps IgG anti-COVID-19 qu'ils aient une goutte épaisse positive ou pas soit 56,0% (42/75) et 52,2% (71/136) respectivement. Conclusion. En cas de suspicion du paludisme en zone impaludée, il parait non négligeable de considérer la COVID-19 comme un diagnostic différentiel.

Paciente con quistes pulmonares y diagnóstico de coinfección con tuberculosis e hidatidosis: reporte de un caso pediátrico / Patient with pulmonary cysts and diagnosis of co-infection with tuberculosis and hydatidosis. Pediatric cases report

Existen numerosas entidades en la población pediátrica que pueden presentarse en forma de quistes o como lesiones de similares características. De estas patologías, las infecciosas son las más frecuentes. Se presenta el caso de una paciente oriunda de Bolivia con migración reciente a la Argentina que presentó una coinfección con tuberculosis e hidatidosis pulmonar. Ambas infecciones se pueden presentar con signos y síntomas similares y, aunque la asociación citada es poco frecuente en la bibliografía, ciertos mecanismos inmunitarios podrían intervenir en la coinfección de parásitos helmintos y micobacterias. Ambas patologías son infecciones prevalentes en nuestra región y deben ser tenidas en cuenta entre los diagnósticos diferenciales ante pacientes con imágenes quísticas o cavitarias pulmonares.

Numerous entities in the pediatric population can present in the form of cysts or as lesions with similar characteristics. Of the pathologies that can cause these images in children, infectious diseases are the most frequent. We present the case of a native of Bolivia with recent immigration to Argentina who presented a pulmonary co-infection with tuberculosis and hydatidosis. Both infections can present with similar signs and symptoms and although this association is rarely reported in the literature, certain immunological mechanisms could intervene in the causal association of co-infection between helminth parasites and mycobacteria. Both pathologies are very prevalent infections in our region and should be taken into account among the differential diagnoses in patients with cystic or cavitary pulmonary diseases.

Comorbilidades infecciosas en la gravedad y mortalidad por Covid-19: análisis del aporte científico en The Lancet Publishing Group / Infectious comorbidities in severity and mortality from Covid-19: analysis of the scientific contribution in The Lancet Publishing Group

El número de casos totales de la enfermedad coronavirus-2019 (Covid-19) sigue aumentando rápidamente, amenazando a miles o millones de personas con condiciones crónicas preexistentes que se ven afectados de manera desproporcionada. Hasta el 2020, el centro de recursos de coronavirus de la Universidad Johns Hopkins informó que en todo el mundo más de 180 países han sido afectados con Covid-19 con más de doce millones de casos confirmados y más de 500,000 muertes. A medida que continúa la investigación relacionada con los posibles factores de riesgo de mortalidad por Covid-19, se hace evidente que las personas con comorbilidades subyacentes, como enfermedades cardiovasculares, hipertensión, diabetes, insuficiencia cardíaca congestiva, enfermedad cerebrovascular, enfermedad renal crónica, enfermedad hepática crónica, cáncer, enfermedad pulmonar obstructiva crónica, el asma y el VIH/SIDA pueden tener un mayor riesgo de muerte por Covid-19. El objetivo de este trabajo es determinar las comorbilidades infecciosas en la gravedad y mortalidad por Covid-19 especialmente asociadas con VIH/SIDA y tubercolosis, respodiendo a la siguiente pregunta: ¿La comunidad científica mundial se ha preocupado por la comorbilidad infecciosa en casos de covid-19 severos y fatales?. Un análisis hecho al grupo de referencias The Lancet Publishing Group fue realizado para dar repuesta a dicha pregunta(AU)

The number of total cases of coronavirus disease-2019 (COVID-19) continues to rise rapidly, threatening thousands or millions of people with pre-existing chronic conditions who are disproportionately affected. As of 2020, the Johns Hopkins University Coronavirus Resource Center reported that worldwide more than 180 countries have been affected with COVID-19 with more than twelve million confirmed cases and more than 500,000 deaths. As research related to potential risk factors for mortality from COVID-19 continues, it becomes clear that people with underlying comorbidities, such as cardiovascular disease, hypertension, diabetes, congestive heart failure, cerebrovascular disease, chronic kidney disease, chronic liver disease, cancer, chronic obstructive pulmonary disease, asthma, and HIV/AIDS may be at increased risk of death from COVID-19. The objective of this work is to determine the infectious comorbidities in severity and mortality from Covid-19, especially associated with HIV/AIDS and tuberculosis, answering the following question: Has the world scientific community been concerned about infectious comorbidity in covid-19 severe and fatal cases? An analysis made to the reference group The Lancet Publishing Group was carried out to answer this question(AU)

Desfechos do tratamento de tuberculose nos casos de coinfecção por HIV na Amazônia Legal / Tuberculosis treatment outcomes in HIV coinfection cases in the Legal Amazon / Resultados del tratamiento de tuberculosis en casos de coinfección por VIH en la Amazonia Legal

Um dos grandes desafios para o controle da coinfecção de tuberculose (TB) e do vírus da imunodeficiência humana (HIV) é o tratamento, que, apesar de ser disponibilizado gratuitamente no Sistema Único de Saúde, apresenta baixos índices de adesão, bem como abandono do tratamento de ambas as doenças por diversos motivos, por exemplo, ausência de vínculo com os serviços de saúde, difícil ingestão dos múltiplos medicamentos e suas possíveis reações adversas, entre outros, consequentemente levando a desfechos desfavoráveis. Nesse sentido, este artigo pretende analisar os desfechos do tratamento de TB em pessoas vivendo com HIV em Rondônia, entre 2008 e 2018. Trata-se de um estudo ecológico com abordagem quantitativa, a partir do levantamento das variáveis clínicas, município de residência e notificação dos casos de coinfecção TB/HIV, com idade igual ou superior a 18 anos, residentes do estado e que não apresentassem a variável "situação de encerramento" em branco. Os dados foram analisados espacialmente no TabWin. Dos 721 casos selecionados, identificou-se baixo percentual de cura (50-84%) e elevado de abandono (6-49%), com tempo médio entre diagnóstico e tratamento de nove dias e, de tratamento, de 158 dias. Somente 25 municípios do estado notificaram casos de coinfecção, embora 34 se caracterizassem como municípios de residência. Com isso, verificam-se centralização das notificações e dificuldades nas estratégias de adesão e vínculo, tal como o tratamento diretamente observado, repercutindo nas ações de controle e, consequentemente, nos desfechos desfavoráveis para o tratamento da TB em pessoas vivendo com HIV em Rondônia.

One of the great challenges for the control of tuberculosis (TB) and human immunodeficiency virus (HIV) co-infection is the treatment, which, despite being available free of charge within the scope of the Brazilian National Health System, has low adherence rates and abandonment of treatment of both diseases for various reasons, for example, lack of a bond with health services, difficulty of ingestion of the multiple medications and their possible adverse reactions, among others, which consequently leads to unfavorable outcomes. In this sense, this article aimed to analyze the outcomes of TB treatment in people living with HIV in Rondônia, between 2008 and 2018. It is an ecological study with a quantitative approach, based on a survey of the clinical variables, municipality of residence and notification of cases of TB/HIV co-infection aged 18 years or over, residents of the state, and who did not have the variable "closure status" blank. Data were spatially analyzed in TabWin. Of the 721 selected cases, a low percentage of cure (50-84%) and a high percentage for abandonment (6-49%) were identified, with a mean time between diagnosis and treatment of nine days and treatment time of 158 days. Only 25 municipalities in the state reported cases of coinfection, although 34 were characterized as the municipality of residence. Thus, there is a centralization of notifications and difficulties in adherence and bonding strategies, such as the treatment directly observed, having repercussions on control actions and, consequently, on unfavorable outcomes for TB treatment in people living with HIV in Rondônia.

Uno de los grandes desafíos para controlar la coinfección de tuberculosis (TB) y del virus de la inmunodeficiencia humana (VIH) es el tratamiento, que, a pesar de ser gratuito en el ámbito del Sistema Único de Salud, presenta bajas tasas de adherencia y abandono de ambas enfermedades, por diversas razones, ya sea por la falta de vinculación con los servicios de salud y múltiples medicamentos de difícil toma y sus posibles reacciones adversas, por ejemplo, que en consecuencia conducen a desenlaces desfavorables. En ese sentido, este estudio tuvo como objetivo analizar los resultados del tratamiento de la TB en personas que viven con el VIH en Rondônia (Brasil), en el periodo entre 2008 y 2018. Este es un estudio ecológico con enfoque cuantitativo, basado en la encuesta de variables clínicas, municipio de residencia y notificación de casos de infección por TB/VIH en pacientes de 18 años o más, residentes en el estado y que no tenían en blanco la variable "estado de cierre". Los datos se analizaron espacialmente en TabWin. De los 721 casos seleccionados se identificó un bajo porcentaje de curación (50-84%) y un alto porcentaje de abandono (6-49%), con un tiempo promedio entre diagnóstico y tratamiento de nueve días y, por tratamiento, de 158 días. Solamente 25 municipios del estado reportaron casos de coinfección, aunque 34 se caracterizaron como municipios de residencia. Esto demuestra haber una centralización de las notificaciones y dificultades en las estrategias de adhesión y vinculación, como el tratamiento directamente observado, teniendo repercusiones en las acciones de control y, consecuentemente, en resultados desfavorables para el tratamiento de la TB en personas que viven con VIH en Rondônia.

Manifestações clínicas da coinfecção entre covid-19 e dengue em adultos: revisão integrativa / Manifestaciones clínicas de la coinfección entre covid-19 y dengue en adultos: revisión integrativa / Clinical manifestations of coinfection between covid-19 and dengue in adults: integrative review

Objetivo: identificar as evidências disponíveis na literatura científica sobre as manifestações clínicas da coinfecção entre COVID-19 e Dengue em adultos. Método: revisão integrativa, realizadas nas bases MEDLINE/PUBMED, LILACS, IBECS, WoS e EMBASE, em junho de 2021. Os descritores "adulto", "Infecções por Coronavírus" e "dengue" junto aos seus sinônimos, foram cruzados por meio de operadores booleanos "AND" e "OR". Resultados: Foram incluídos 23 estudos, predominando estudos de caso 19 (82,6%). As principais manifestações clínicas identificadas a partir dos estudos foram: febre, cefaleia, dispneia, tosse, mialgia, dor retro orbital e rash cutâneo. Além de achados laboratoriais como: trombocitopenia, linfopenia e leucopenia. Conclusão: a coinfecção COVID-19 e Dengue foi identificada e aponta-se a necessidade da busca imediata do diagnóstico diferencial, para prevenir os agravos clínicos e diminuir os desfechos inesperados.

Objective: to identify the evidence available in the scientific literature on the clinical manifestations of co-infection between Covid-19 and dengue in adults. Method: integrative review, carried out in the MEDLINE/PUBMED, LILACS, IBECS, WoS and EMBASE databases, in June 2021. The descriptors "adult", "Coronavirus infections" and "dengue" with their synonyms were crossed by means of operators Booleans AND and OR. Results: 23 studies were included, with a predominance of 19 case studies (82.6%).The main clinical manifestations identified from the studies were: fever, headache, dyspnea, cough, myalgia, retro orbital pain, and skin rash. In addition to laboratory findings such as: thrombocytopenia, lymphopenia, and leukopenia. Conclusion: covid-19 and Dengue coinfection was identified and the need for an immediate search for a differential diagnosis is pointed out, in order to prevent clinical problems and reduce unexpected outcomes.

Objetivo: identificar la evidencia disponible en la literatura científica sobre las manifestaciones clínicas de la coinfección entre Covid-19 y Dengue en adultos. Método: revisión integrativa, realizada en las bases de datos MEDLINE / PUBMED, LILACS, IBECS, WoS y EMBASE, en junio de 2021. Los descriptores "adulto", "Infecciones por coronavirus" y "dengue" con sus sinónimos fueron cruzados mediante operadores booleanos "AND" y "OR". Resultados: se incluyeron 23 estudios, con predominio de 19 estudiosde casos (82,6%). Las principales manifestaciones clínicas identificadas en los estudios fueron: fiebre, cefalea, disnea, tos, mialgia, dolor retro orbital y erupción cutánea. Además de los hallazgos de laboratorio como: trombocitopenia, linfopenia y leucopenia. Conclusión: se identificó la coinfección por Covid-19 y Dengue y se señala la necesidad de una búsqueda inmediata de un diagnóstico diferencial, con el fin de prevenir problemas clínicos y reducir resultados inesperados.

Infecção latente da tuberculose em pessoas vivendo com HIV no Paraná: caracterização do perfil clínico-epidemiológico / Infección tuberculosa latente en personas que viven con VIH en Paraná: caracterización del perfil clínico-epidemiológico / Latent tuberculosis infection in people living with HIV in Paraná: characterization of clinical-epidemiological profile

Objetivo: caracterizar perfil clínico-epidemiológico das pessoas vivendo com HIV com registro de tratamento da Infecção Latente pelo Mycobacterium tuberculosis no Estado do Paraná em 2019 e 2020. Método: estudo descritivo, com dados do Sistema de Informação Nacional para notificação das pessoas em tratamento para tuberculose, disponibilizados pela Secretaria Estadual de Saúde do Paraná. A análise dos dados foi descritiva. Resultados: houve redução significativa do número de pessoas em tratamento, com perfil predominante de homens brancos com idade média de 41 anos, com radiografia de tórax normal, imunizados contra tuberculose, sem realização de prova tuberculínica, em uso de isoniazida, sem histórico de contato de tuberculose e com tratamento da fase latente. Conclusões: evidencia-se a importância da ação conjunta entre Programas de Controle de HIV e tuberculose, com foco na ampliação do tratamento preventivo e na educação em saúde para conscientização, em especial de homens adultos.(AU)

Objective: to characterize clinical-epidemiological profile of people living with HIV with a record of treatment for Latent Infection by Mycobacterium tuberculosis in the State of Paraná in 2019 and 2020. Method: descriptive study, with data from the National Information System for notifying people undergoing treatment for tuberculosis, made available by the State Department of Health of Paraná. Data analysis was descriptive. Results: there was a significant reduction in the number of people undergoing treatment, with a predominant profile of white men with a mean age of 41 years, with normal chest X-rays, immunized against tuberculosis, without tuberculin skin testing, using isoniazid, no history of contact with tuberculosis and, with treatment of the latent phase. Conclusions: the importance of joint action between HIV and Tuberculosis Control Programs is evident, with a focus on expanding preventive treatment and health education for awareness, especially for adult men.(AU)

Objetivo: caracterizar perfil clínico-epidemiológico de personas que viven con VIH con registro de tratamiento para Infección Latente por Mycobacterium tuberculosis en el Estado de Paraná en 2019 y 2020. Método: estudio descriptivo, con datos del Sistema Nacional para notificar personas en tratamiento por tuberculosis, puesto a disposición por la Secretaría de Estado de Salud de Paraná. El análisis fue descriptivo. Resultados: hubo una reducción significativa en el número de personas en tratamiento, con perfil predominante de hombres blancos, edad media de 41 años, con radiografías de tórax normales, inmunizados contra la tuberculosis, sin prueba cutánea de la tuberculina, usando isoniazida, sin antecedentes de contacto de tuberculosis y con tratamiento de la fase latente. Conclusiones: se evidencia la importancia de la acción conjunta entre Programas de Control del VIH y la Tuberculosis, con foco en ampliar el tratamiento preventivo y la educación en salud para la concientización, especialmente de hombres adultos.(AU)

Neumonía asociada a ventilación mecánica en pacientes con neumonía grave por SARS-CoV-2 / Ventilation associated pneumonia in patients with severe SARS-CoV-2 pneumonia

Introducción: Los pacientes con COVID-19 pueden evolucionar hacia una falla respiratoria aguda grave y requerir ventilación mecánica invasiva (VMI). La complicación más frecuente en estos pacientes es la neumonía asociada a ventilación mecánica (NAVM), con incidencias reportadas más altas que en la época pre-COVID. El objetivo de este estudio es reportar la incidencia, tasa de incidencia y microbiología de la NAVM en pacientes en VMI con COVID-19. Métodos: Se incluyeron a todos los pacientes con neumonía grave y PCR (+) para SARS-CoV-2 que ingresaron y requirieron VMI entre marzo y julio del 2021 en el Instituto Nacional del Tórax (INT). Se recolectaron datos demográficos, clínicos y de laboratorio de la ficha electrónica. Se registraron y caracterizaron los casos de neumonía asociado a la ventilación mecánica. Resultados: Se incluyeron 112 pacientes de los cuales el 42,8% presentó NAVM, con una tasa de incidencia de 28,8/1.000 días de VMI. Los microorganismos aislados más frecuentes fueron Klebsiella pneumoniae (29,6%), Staphylococcus aureus (21,8%) y Pseudomonas aeruginosa (12,5%). Los pacientes que cursaron NAVM estuvieron casi el doble de tiempo en VMI, pero sin presentar aumento de la mortalidad. Conclusión: La NAVM es una complicación frecuente en los pacientes con neumonía grave asociada a COVID-19. La microbiología de estas entidades no ha cambiado respecto a la era pre-pandémica. Estos resultados cobran relevancia en el inicio y suspensión de antibióticos en este grupo de pacientes.

Introduction: Patients with COVID-19 can progress to severe acute respiratory failure and require invasive mechanical ventilation (IMV). The most frequent complication in these patients is ventilator-associated pneumonia (VAP), with higher reported incidences than in the pre-COVID era. The objective of this study is to report the prevalence, incidence rate and microbiology of VAP in patients on IMV with COVID-19. Methods: Patients with severe pneumonia and PCR (+) for SARS-CoV-2 who were admitted to IMV between march and july 2021 at the Instituto Nacional del Tórax (Chile) were included. Demographic, clinical and laboratory data from electronic records were collected. Cases of pneumonia associated with mechanical ventilation were recorded and characterized. Results: 112 patients were included, 42.8% of them presented VAP with an incidence rate of 28.8/1,000 IMV days. The most frequent isolated microorganisms were Klebsiella pneumoniae (29.6%), Staphylococcus aureus (21.8%) and Pseudomonas aeruginosa (12.5%). Patients who underwent VAP spent almost twice as long on IMV, although they had not increase in mortality. Conclusion: VAP is a common complication in patients with severe pneumonia associated with COVID-19. The microbiology of these entities has not changed from the pre-pandemic era. These results become relevant in the initiation and suspension of antibiotics in this group of patients.

Guía clínica para la atención pediátrica de tuberculosis y coinfección TB-VIH. 2ª. ed. / Clinical guideline for pediatric care of tuberculosis and TB-HIV coinfection. 2nd. ed

El Salvador está implementando la estrategia «Fin de la TB¼, que abarca un conjunto de intervenciones que pueden adaptarse plenamente a nivel nacional. Cuenta con diez componentes organizados en tres pilares y cuatro principios fundamentales; requiere la rectoría del SNIS, coordinación sólida con las organizaciones de la sociedad civil y las comunidades, un enfoque basado en derechos humanos, ética y equidad, y la adaptación nacional de la estrategia y las metas. La presente guía unifica conocimientos sobre la enfermedad y criterios de diagnóstico, tratamiento de la TB y la coinfección TB-VIH, para aplicar las medidas de prevención de la TB dentro de los establecimientos del Sistema Nacional Integrado de Salud (SNIS)

El Salvador is implementing the "End TB" strategy, which encompasses a set of interventions that can be fully adapted at the national level. It has ten components organized into three pillars and four fundamental principles; It requires leadership of the SNIS, solid coordination with civil society organizations and communities, an approach based on human rights, ethics and equity, and the national adaptation of the strategy and goals. This guide unifies knowledge about the disease and diagnostic criteria, treatment of TB and TB-HIV coinfection, to apply TB prevention measures within the establishments of the National Integrated Health System (SNIS)

Cervicitis necrótica por co-infección de virus herpes simplex 2 y Mycoplasma genitalium / Necrotic cervicitis for co-infection of herpes simplex virus 2 and Mycoplasma genitalium

Resumen Las cervicitis es una condición frecuente causada principalmente por agentes de transmisión sexual. Su presentación clínica varía desde cuadros asintomáticos hasta procesos inflamatorios extensos, que incluso asemejan un tumor maligno. Presentamos el caso de una adolescente que presentó úlceras genitales, síntomas generales y cérvix necrótico con aspecto tumoral. Los estudios de laboratorio confirmaron una co-infección por virus herpes simplex 2 (HSV-2) y Mycoplasma genitalium. El estudio histológico descartó una neo- plasia. Evolucionó favorablemente al tratamiento antimicrobiano, con recuperación progresiva del aspecto del cérvix. La cervicitis en raras ocasiones se presenta con compromiso necrótico. La co-infección por HSV-2 y M. genitalium, en este caso, pudo ser el determinante del daño cervical y la necrosis. Una evaluación acuciosa y estudio con exámenes diagnósticos de alta sensibilidad y especificidad permitieron hacer un diagnóstico y tratamiento adecuado.

Abstract Cervicitis is a frequent condition caused mainly by sexually trans- mitted agents. The clinical spectrum varies from absence of symptoms to extensive inflammatory processes that may simulate a malignant neoplasm. We present a clinical case of an adolescent with genital ulcers and systemic disease. Speculoscopy revealed a tumoral-looking cervix. Laboratory studies confirm infection with herpes simplex virus 2 (HSV-2) and Mycoplasma genitalium, together with a histological study that ruled out neoplasia. It progresses favorably to antimicrobial treatment, with recovery of the appearance of the cervix. Cervicitis rarely presents with necrotic involvement. Co-infection with HSV-2 and M. genitalium infection may have been the determinant of cervical damage and the necrotic appearance. A thorough evaluation and study with highly sensitive and specific diagnostic tests allowed an adequate diagnosis and treatment.

¿Es posible la coinfección o un diagnóstico erróneo por dengue y COVID-19? Una revisión de reporte de casos / Is dengue and COVID-19 coinfection or misdiagnosis possible? A review on reported cases

INTRODUCCIÓN: El nuevo coronavirus ha continuado propagándose por todo el mundo donde existen otras enfermedades endémicas que han sido una carga para la salud pública durante muchos años. Como cualquier infección, se habría esperado encontrar en coinfección con algunas de éstas. Específicamente, los países tropicales y subtropicales han venido manejando la carga del dengue a medida que aumentan los picos con períodos de tiempo más cortos. OBJETIVO: Resumir la evidencia que existe en la coinfección relacionada con el SARS-CoV-2 y el virus del dengue. METODOLOGÍA: Se realizó una revisión narrativa en bases de datos sobre reportes de coinfección y diagnóstico erróneo de SARS-CoV-2 y el dengue dado que la temporada de lluvias cada año aumenta la prevalencia de infecciones virales en países endémicos. Informes recientes incluso han descrito casos positivos en uno de estas infecciones que luego resultaron en falso positivo. Una prueba positiva para COVID-19 o fiebre del dengue en áreas endémicas no debe excluir la otra infección. CONCLUSIÓN: A partir de ahora, estos dos deberían ser considerados como un diagnóstico diferencial y esto debe generar preocupación de salud pública por su coinfección en países endémicos para reforzar la promoción y prevención a las comunidades y mitigar estas enfermedades.

BACKGROUND: Novel coronavirus has continued to spread throughout the world where there are other endemic diseases that have been a burden to public health for many years. As any infection, it was expected there could be coinfection between these. Tropical and subtropical countries are currently managing with dengue as peaks increase with shorter periods of time. AIM: To summarize the evidence that exists in the co-infection related to SARS-CoV-2 and the dengue virus. METHOD: We conducted a narrative review in data bases about reports of coinfection and misdiagnosis of SARS-CoV-2 and dengue virus given the fact that rainy season every year increase the prevalence of viral infections in endemic countries. Recent reports have even described positive cases in one of these infections that later resulted in false positive. A positive test for COVID-19 or dengue fever in endemic areas should not exclude the other infection. CONCLUSION: From now on, these two should be considered as a differential diagnosis and this should raise public health concern for COVID-19 and dengue coinfection in endemic countries to reinforce promotion and prevention to communities to prevent these diseases.

Prevalencia de Fasciola hepatica y Paramphistomidae en bovinos de doble propósito en una hacienda del trópico bajo andino colombiano / Prevalence of Fasciola hepatica and Paramphistomidae in dual purpose cattle in a farm in the Colombian low Andean tropic

RESUMEN En muchos países la fasciolosis y la paramfistomosis representan un grave problema para la salud del sector pecuario. En Colombia hay registros de ambas distomatosis en bovinos, la mayoría en el trópico alto andino, las cuales generan pérdidas econômicas anuales cercanas a 40 000 000 000 COP. El objetivo de esta investigación fue determinar la prevalencia de fasciolosis y paramfistomosis en vacunos de la hacienda La Candelaria, Caucasia (Colombia), y la presencia de caracoles hospederos intermediarios. Para cumplirlo, se realizó un estudio descriptivo de corte transversal con muestreo no probabilístico por conveniencia. Se recolectaron heces de los animales y se hizo el diagnóstico mediante la técnica modificada de Dennis. Se establecieron las prevalencias de los digeneos de acuerdo con el sexo, peso, edad y raza. Se recolectaron caracoles dulciacuícolas en la zona estudiada y se identificaron por morfologia. Se analizaron 466 muestras fecales de 178 bovinos, de las razas Cebú (Bos indicus), BON (blanco orejinegro) y del cruce entre ellas. Se diagnosticaron F. hepatica y Paramphistomidae con prevalencias del 2,2% y 30,9%, respectivamente. En el 1,1% de los vacunos se diagnosticó coinfección. Ambas trematodosis prevalecieron en las hembras (p = 0,03). Se identificaron moluscos dulciacuícolas Ampullariidae, Physidae y Planorbidae sin estadios larvarios de digeneos. Se concluyó que los bovinos de doble propósito de la hacienda La Candelaria están expuestos a F. hepatica y Paramphistomidae, y, probablemente, se infectan en los predios de la hacienda. Paramphistomidae es más prevalente que F. hepatica, lo cual concuerda con lo descrito en algunos estudios realizados en hatos del trópico alto andino colombiano. Paramphistomidae se encontró en todos los grupos etarios.

ABSTRACT Fasciolosis and paramphistomosis are a major health problem for the livestock economy worldwide. In Colombia, both distomatosis are reported in cattle, particularly in high Andean tropics, with annual economic losses close to COP 40 billion. The goal of this study was to determine the prevalence of fasciolosis and paramphistomosis in cattle from La Candelaria farm, Caucasia (Colombia), and the presence of intermediate host snails. A descriptive cross-sectional study was carried out with non-probability convenience sampling. Stool samples were collected from the animals and the diagnosis was made using the modified Dennis technique. Digenea prevalence were determined according to sex, weight, age, and race. Freshwater snails were collected in the studied area and were identified by morphology. 400 and 66 fecal samples from 178 bovines of the Zebu (Bos indicus), BON (white-eared white) breeds and the cross between them were analyzed. Fasciola hepatica and Paramphistomidae were diagnosed with a prevalence of 2,2% and 30,9%, respectively. Coinfection was diagnosed in 1,1% of the cattle. Both trematodosis were most frequent in females (p = 0,03). Freshwater molluscs Ampullariidae, Physidae and Planorbidae without digenea larval stages were identified. It was concluded that dual-purpose cattle from La Candelaria farm are exposed to F. hepatica and Paramphistomidae and are probably infected on the farm grounds. Paramphistomidae was more prevalent than F. hepatica, which agrees with other studies in herds from the Colombian high Andean tropics. Paramphistomidae was found in all age groups.

Evaluation of Strongyloides stercoralis infection in patients with HTLV-1 / Evaluación de la infestación por Strongyloides stercoralis en pacientes con HTLV-1

Introduction: Individuals infected with the human T-lymphotropic virus type 1 (HTLV-1) may present severe and disseminated forms of Strongyloides stercoralis infection with low therapeutic response. Objective: To investigate the S. stercoralis infection and the seroprevalence of IgG anti-S. stercoralis antibodies in individuals infected with HTLV-1 attending the Reference Center for HTLV-1 (CHTLV) in Salvador, Bahia, Brazil. Materials and methods: We conducted a cross-sectional study in 178 HTLV-1-infected individuals treated at the HTLV specialized center between January, 2014, and December, 2018. The parasitological diagnosis of S. stercoralis was performed using the Hoffman, Pons and Janer, agar plate culture, and Baermann-Morais methods. The IgG anti-S. stercoralis detection was performed using an in house enzyme-linked immunosorbent assay (ELISA). The HTLV-1 infection was diagnosed using a commercial ELISA and confirmed by Western blot. Results: The frequency of S. stercoralis infection was 3.4% (6/178). Individuals infected with S . stercoralis from rural areas (50.0%; 3/6) also showed S. stercoralis hyperinfection (>3,000 larvae/gram of feces). The frequency of circulating anti-S. stercoralis IgG antibodies was 20.8% (37/178). Conclusions: HTLV-1-infected people living in precarious sanitary conditions are more prone to develop severe forms of S. stercoralis infection. Considering the high susceptibility and unfavorable outcome of the infection in these individuals, the serological diagnosis for S. stercoralis should be considered when providing treatment.

Introducción. Los individuos infectados por el virus linfotrópico T humano tipo 1 (HTLV-1) pueden presentar formas graves y diseminadas de infestación por Strongyloides stercoralis con poca mejoría terapéutica. Objetivo. Investigar la infestación por S. stercoralis y la seroprevalencia de IgG anti-S. stercoralis en individuos infectados por HTLV-1 atendidos en el Centro de Referencia para HTLV-1 (CHTLV), en Salvador, Bahía, Brasil. Materiales y métodos. Se hizo un estudio transversal con 178 individuos infectados por HTLV-1 atendidos en el centro especializado de HTLV entre enero de 2014 y diciembre de 2018. El diagnóstico parasitológico de S. stercoralis se hizo mediante los métodos de Hoffman, Pons y Janer, cultivo en placa de agar y Baermann-Morais. Para la detección de IgG anti-S. stercoralis, se utilizó una prueba casera de inmunoabsorción ligada a enzimas (ELISA). La infección por HTLV-1 se diagnosticó usando un ELISA comercial y se confirmó mediante Western blot. Resultados. La frecuencia de infestación por S. stercoralis fue del 3,4 % (6/178). Además, los individuos infestados por S. stercoralis provenientes de la zona rural (50,0 %; 3/6) también mostraron hiperinfestación por S. stercoralis (>3.000 larvas/gramo de heces). La frecuencia de anticuerpos IgG anti-S. stercoralis fue del 20,8 % (37/178). Conclusiones. Las personas infectadas por HTLV-1 que viven en condiciones sanitarias precarias son más propensas a desarrollar formas graves de infestación por S. stercoralis. Teniendo en cuenta la gran vulnerabilidad y el resultado desfavorable de la infección en estos individuos, se debe considerar el diagnóstico serológico de S. stercoralis para administrar el tratamiento

Serological survey of Neospora caninum and Toxoplasma gondii in shelter-housed cats infected with feline immunodeficiency virus, Brazil / Inquérito sorológico para Neospora caninum e Toxoplasma gondii em um abrigo de gatos infectados com o vírus da imunodeficiência felina, Brasil

Felines play a leading role in the epidemiology of Toxoplasma gondii infection, but there is scarce information about the epidemiology of Neospora caninum, particularly in feline immunodeficiency virus (FIV)-infected cats. Cats seropositive to T. gondii do not usually show symptoms unless they are immunosuppressed, such as FIV-infected cats. The same relationship remains poorly known for N. caninum, although it has been associated with neurological disorders in HIV-infected people. Since FIV-infected cats are prone to develop encephalitis of unknown etiology, this study aimed to evaluate the presence of specific antibodies to T. gondii and N. caninum in a shelter for stray cats naturally infected with FIV. A total of 104 serum samples from cats living in a shelter, located in São Paulo city (Brazil), was assessed for T. gondii and N. caninum specific antibody by indirect fluorescent-antibody test (IFAT). Of the 104 cats, 25 (24%) were infected with FIV and, aside from these, 8 (32%) had antibodies against T. gondii (titers from 16 to 128). Only 1 (4%) of the FIV-infected cats had antibodies against N. caninum, which was the first record of coinfection. Among the FIV-naïve cats, 11 (14%) were positive for T. gondii(titers from 16 to 256) and only 1 (1.2%) had antibodies against N. caninum. Serologically positive reactions to T. gondii and N. caninum were not correlated with age or sex (p>0.05), and there was no correlation between FIV and the occurrence of anti-T. gondii or anti-N. caninum antibodies (p>0.05). Further studies encompassing larger cat populations from different origins and locations are essential to clarify the prevalence of T. gondii and N. caninum antibodies in FIV-positive cats.(AU)

Os felinos têm um papel importante na epidemiologia da infecção por Toxoplasma gondii, mas pouco se sabe sobre a epidemiologia da infecção por Neospora caninum em gatos, particularmente em gatos infectados com o vírus da imunodeficiência felina (FIV). Gatos soropositivos para Toxoplasma gondii geralmente não apresentam sintomas a não ser que estejam imunossuprimidos, como gatos infectados com FIV. A mesma relação ainda é pouco conhecida para N. caninum, embora tenha sido associada a distúrbios neurológicos em pessoas infectadas pelo HIV. Considerando que gatos infectados com FIV são propensos a desenvolver encefalite de etiologia desconhecida, o presente estudo teve como objetivo avaliar a presença de anticorpos específicos para T. gondii e N. caninum em gatos infectados com FIV. Um total de 104 amostras de soro de gatos residentes em um abrigo na cidade de São Paulo, Brasil, foram avaliadas para a presença de anticorpos contra T. gondii e N. caninum pelo teste de imunofluorescência indireta (RIFI). Dos 104 gatos, 25 (24%) estavam infectados com FIV e destes 8, (32%) tinham anticorpos contra T. gondii (titulação entre 16 e 128). Apenas 1 (4%) dos gatos infectados com FIV apresentava anticorpos contra N. caninum, sendo este o primeiro registro dessa coinfecção. Entre os gatos não infectados com FIV, 11 (14%) foram positivos para T. gondii (titulação entre 16 e 256) e apenas 1 (1,2%) tinha anticorpos contra N. caninum. A reação sorologicamente positiva para T. gondii e N. caninum não foi correlacionada com a idade ou sexo (p> 0,05), nem houve correlação entre FIV e ocorrência de anticorpos para T. gondii ou N. caninum(p> 0,05). Estudos subsequentes abrangendo populações maiores de gatos de diferentes origens e locais são essenciais para esclarecer a prevalência de anticorpos contra T. gondii e N. caninum em animais acometidos por FIV.(AU)

ERRATUM: Severe monkeypox case associated with recent laboratory diagnosis of HIV: case report / ERRATA: Caso grave de monkeypox associado ao diagnóstico laboratorial recente de HIV: relato de caso

Introduction: Monkeypox is a zoonosis caused by the monkeypox virus. The first confirmed human case was in 1970, when the virus was isolated from a child in the Democratic Republic of the Congo. Since the beginning of May 2022, a large and unexpected outbreak has been documented globally, with the first cases initially described in the UK reaching around 70 countries today. The causes of this explosive increase in patients are not well understood, but exceed more than ten thousand10,000 infected by the third week of July 2022. Clinical and epidemiological presentations have been distinct from endemic cases and from small outbreaks previously described in non- endemic areas. Objective: The aim of this study was to describe the evolutionary and epidemiological, clinical characteristics of Monkeypox and human immunodeficiency virus co-infection in a patient treated at an STI/AIDS Reference Service in São Paulo, Brazil. Methods: information contained in this study was obtained through a review of the medical records, interviews with the patient, photographic record of the diagnostic methods, to which the patient was submitted and review of the literature. Results: A Brazilian man, with no epidemiological history of travel who was diagnosed with Monkeypox virus through polymerase chain reaction. At the same time of this diagnosis, he received a laboratory diagnosis of human immunodeficiency virus, Chlamydia Urethritis, and Late Latent Syphilis. Conclusion: To reduce the risk of the dissemination of Monkeypox, strategies at the public health level are necessary, with the dissemination of information and the development of prevention projects with targeted information and recommendations for vulnerable populations, especially men who have sex with men, with great prudence, seeking not to favor the development of stigmas as already experienced at the beginning of the human immunodeficiency virus epidemic.

Introdução: Monkeypox é uma zoonose causada pelo vírus monkeypox. O primeiro caso humano confirmado foi em 1970, quando o vírus foi isolado de uma criança na República Democrática do Congo. Desde o início de maio de 2022, um surto grande e inesperado tem sido documentado globalmente, com os primeiros casos inicialmente descritos no Reino Unido atingindo hoje cerca de 70 países. As causas desse aumento explosivo de pacientes não estão bem esclarecidas, mas ultrapassaram 10 mil infectados até a terceira semana de julho de 2022. As apresentações clínicas e epidemiológicas têm sido distintas dos casos endêmicos e dos pequenos surtos previamente descritos em áreas não endemicas. Objetivo: Neste relato descrevemos as características clínicas evolutivas e epidemiológicas da coinfecção do Monkeypox e do imunodeficiência humana em um paciente atendido em um serviço de referência em infecções sexualmente transmissíveis ­ IST/Aids de São Paulo, Brasil. Métodos: as informações dos métodos contidas neste estudo foram obtidas por meio de revisão dos prontuários, entrevistas com o paciente, prontuário fotográfico dos métodos diagnósticos, aos quais o paciente foi submetido e revisão da literatura. Resultados: Homem brasileiro, sem antecedente epidemiológico de viagem, foi diagnosticado com Monkeypox por meio de reação em cadeia da polimerase. Simultaneamente a esse diagnóstico, recebeu diagnóstico laboratorial de vírus da imunodeficiência humana, uretrite por clamídia e sífilis latente tardia. Conclusão: Para reduzir o risco de disseminação do Monkeypox, são necessárias estratégias no âmbito da saúde pública, com disseminação da informação e elaboração de projetos de prevenção com informações direcionadas e recomendações para populações vulneráveis, especialmente homens que fazem sexo com homens, com bastante prudência, buscando não favorecer o desenvolvimento de estigmas como os já vivenciados no início da epidemia de imunodeficiência humana.

Severe monkeypox case associated with recent laboratory diagnosis of HIV: case report / Caso grave de monkeypox associado ao diagnóstico laboratorial recente de HIV: relato de caso

Monkeypox is a zoonosis caused by the smallpox virus. The first confirmed human case was in 1970, when the virus was isolated from a child in the Democratic Republic of the Congo. Since the beginning of May 2022, a large and unexpected outbreak has been documented globally, with the first cases initially described in the UK reaching around 70 countries today. The causes of this explosive increase in patients are not well understood, but exceed more than ten thousand10,000 infected by the third week of July 2022. Clinical and epidemiological presentations have been distinct from endemic cases and from small outbreaks previously described in non- endemic areas. Objective: The aim of this study was to describe the evolutionary and epidemiological, clinical characteristics of Monkeypox and human immunodeficiency virus co-infection in a patient treated at an STI/AIDS Reference Service in São Paulo, Brazil. Methods: information contained in this study was obtained through a review of the medical records, interviews with the patient, photographic record of the diagnostic methods, to which the patient was submitted and review of the literature. Results: A Brazilian man, with no epidemiological history of travel who was diagnosed with Monkeypox virus through polymerase chain reaction. At the same time of this diagnosis, he received a laboratory diagnosis of human immunodeficiency virus, Chlamydia Urethritis, and Late Latent Syphilis. Conclusion: To reduce the risk of the dissemination of Monkeypox, strategies at the public health level are necessary, with the dissemination of information and the development of prevention projects with targeted information and recommendations for vulnerable populations, especially men who have sex with men, with great prudence, seeking not to favor the development of stigmas as already experienced at the beginning of the human immunodeficiency virus epidemic.

Monkeypox é uma zoonose causada pelo vírus varíola. O primeiro caso humano confirmado foi em 1970, quando o vírus foi isolado de uma criança na República Democrática do Congo. Desde o início de maio de 2022, um surto grande e inesperado tem sido documentado globalmente, com os primeiros casos inicialmente descritos no Reino Unido atingindo hoje cerca de 70 países. As causas desse aumento explosivo de pacientes não estão bem esclarecidas, mas ultrapassaram 10 mil infectados até a terceira semana de julho de 2022. As apresentações clínicas e epidemiológicas têm sido distintas dos casos endêmicos e dos pequenos surtos previamente descritos em áreas não endemicas. Objetivo: Neste relato descrevemos as características clínicas evolutivas e epidemiológicas da coinfecção do Monkeypox e do imunodeficiência humana em um paciente atendido em um serviço de referência em infecções sexualmente transmissíveis ­ IST/Aids de São Paulo, Brasil. Métodos: as informações dos métodos contidas neste estudo foram obtidas por meio de revisão dos prontuários, entrevistas com o paciente, prontuário fotográfico dos métodos diagnósticos, aos quais o paciente foi submetido e revisão da literatura. Resultados: Homem brasileiro, sem antecedente epidemiológico de viagem, foi diagnosticado com Monkeypox por meio de reação em cadeia da polimerase. Simultaneamente a esse diagnóstico, recebeu diagnóstico laboratorial de vírus da imunodeficiência humana, uretrite por clamídia e sífilis latente tardia. Conclusão: Para reduzir o risco de disseminação do Monkeypox, são necessárias estratégias no âmbito da saúde pública, com disseminação da informação e elaboração de projetos de prevenção com informações direcionadas e recomendações para populações vulneráveis, especialmente homens que fazem sexo com homens, com bastante prudência, buscando não favorecer o desenvolvimento de estigmas como os já vivenciados no início da epidemia de imunodeficiência humana